Company: LIMN
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001104659-25-010605
Chunk: 453

Company: Liminatus Pharma, Inc.
Filing Date: 2025-02-07
Form: 424B3
Chunk 453
---
 F-29

TABLE OF CONTENTS

IRIS ACQUISITION CORP
STATEMENTS OF OPERATIONS

| ​                                                                                                          
 ​                                                                                                          | ​ 
 ​ | ​ 
 ​ | For the years ended December 31, 
 2023                             |   |            |   | ​ | ​ | 2022 |   |            |   | ​ 
 ​ |
|:-----------------------------------------------------------------------------------------------------------|:--|:--|:---------------------------------|:--|-----------:|:--|:--|:--|:-----|:--|-----------:|:--|:--|
| Formation and operating costs                                                                              | ​ | ​ | ​                                | $ | -2,586,211 | ​ | ​ | ​ | ​    | $ | -2,452,467 | ​ | ​ |
| Forgiveness of unrelated vendor payables                                                                   | ​ | ​ | ​                                | ​ |    275,000 | ​ | ​ | ​ | ​    | ​ |    579,989 | ​ | ​ |
| Loss from operations                                                                                       | ​ | ​ | ​                                | ​ | -2,311,211 | ​ | ​ | ​ | ​    | ​ | -1,872,478 | ​ | ​ |
| Other income (expense):                                                                                    | ​ | ​ | ​                                | ​ |          ​ | ​ | ​ | ​ | ​    | ​ |          ​ | ​ | ​ |
| Unrealized gain on change in fair value of warrant liabilities                                             | ​ | ​ | ​                                | ​ |    566,202 | ​ | ​ | ​ | ​    | ​ |  9,586,864 | ​ | ​ |
| Unrealized gain on change in fair value of derivative liability                                            | ​ | ​ | ​                                | ​ |    102,226 | ​ | ​ | ​ | ​    | ​ |          — | ​ | ​ |
| Interest income on marketable securities held in Trust Account                                             | ​ | ​ | ​                                | ​ |    553,641 | ​ | ​ | ​ | ​    | ​ |  3,074,691 | ​ | ​ |
| Interest expense                                                                                           | ​ | ​ | ​                                | ​ |   -103,089 | ​ | ​ | ​ | ​    | ​ |          — | ​ | ​ |
| Total other income (expense)                                                                               | ​ | ​ | ​                                | ​ |  1,118,980